Indoximod clinical trials
Also written D-1MT.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses indoximod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 5
NewLink Genetics Corporation (7) · H. Lee Moffitt Cancer Center and Research Institute (2) · National Cancer Institute (NCI) (2) · Masonic Cancer Center, University of Minnesota (1)
Often tested with
Tested in the same studies.
Adenovirus-p53 Transduced Dendritic Cell Vaccine (2) · Temozolomide (1) · Docetaxel (1) · Paclitaxel (1) · Tergenpumatucel-L (1)
Studies
Open first, then newest update. How each study uses indoximod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic MelanomaCompletedPhase 1/2NewLink Genetics CorporationNCT02073123Written as Indoximod
- Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic CancerCompletedPhase 1/2NewLink Genetics CorporationNCT02077881Written as Indoximod
- Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain TumorsCompletedPhase 1/2NewLink Genetics CorporationNCT02052648Written as Indoximod
- A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic MelanomaTerminatedPhase 2NewLink Genetics CorporationNCT03301636Written as Indoximod
- Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung CancerTerminatedPhase 1NewLink Genetics CorporationNCT02460367Written as Indoximod
- Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast CancerCompletedPhase 2NewLink Genetics CorporationNCT01792050Written as Indoximod
- IDO Inhibitor Study for Relapsed or Refractory Solid TumorsTerminatedPhase 1NewLink Genetics CorporationNCT00739609Written as 1-methyl-D-tryptophan
- Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate CancerCompletedPhase 2Masonic Cancer Center, University of MinnesotaNCT01560923Written as Indoximod
- Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast CancerCompletedPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT01042535Written as 1-methyl-d-tryptophan
- C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast CancerWithdrawnNot applicableH. Lee Moffitt Cancer Center and Research InstituteNCT01302821Written as 1-methyl-D-tryptophan
- 1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By SurgeryCompletedPhase 1National Cancer Institute (NCI)NCT00567931Written as 1-methyl-d-tryptophan
- 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01191216Written as 1-methyl-d-tryptophan
Given beside what is tested · 4 — indoximod is usual care or a partner of the new treatment
- Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain CancerRecruitingPhase 1Theodore S. JohnsonNCT05106296Written as Indoximod
- Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPGActive, not recruitingPhase 2Theodore S. JohnsonNCT04049669Written as Indoximod
- Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain TumorsCompletedPhase 1NewLink Genetics CorporationNCT02502708Written as Indoximod
- Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male VolunteersCompletedEarly Phase 1NewLink Genetics CorporationNCT03852446Written as Indoximod HCL (F2) tablets
Codes
What other systems call indoximod · ClinicalTrials.gg INT005202
- UNII (FDA) TX5CYN1KMZINDOXIMODConfirmed FDA, Wikidata
- Wikidata Q27078057indoximodConfirmed FDA, Wikidata
- NCI Thesaurus C71535IndoximodOne source FDA
- DrugBank DB12827One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | TX5CYN1KMZ | INDOXIMOD | Confirmed FDA, Wikidata |
| Wikidata | Q27078057 | indoximod | Confirmed FDA, Wikidata |
| NCI Thesaurus | C71535 | Indoximod | One source FDA |
| DrugBank | DB12827 | — | One source Wikidata |
Also registered as n-1-methyl-l-tryptophan (UNII XD0FY1J13B).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.